Oral cabozantinib 40 mg once daily plus atezolizumab 1,200 mg intravenous (IV ... Follow-up duration was calculated using the following formula: (cutoff date – treatment initiation date + 1) ÷ 30.4375 ...
Patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab-bevacizumab treatment were more likely to experience variceal bleeding if they had a low platelet count, main portal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results